Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of ADC118 Tablets in Healthy Chinese Volunteers Under Fasting Conditions
NCT07753902Phase 1Completed
- Sponsor
- Aidea Pharma
- Start
- Apr 2026
- Primary completion
- May 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ADC118 in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Aidea Pharma. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration and 1 more. Started Apr 2026; status: completed.
02
Drugs
ADC118
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07753902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07753902.